@article{Tetikkurt_Yanardag_Sayman_Bilir_Tetikkurt_Bilgic_Kubat_Bilgin_2020, title={Diagnostic utility of 68Ga-citrate and 18FDG PET/CT in sarcoidosis patients}, volume={90}, url={https://www.monaldi-archives.org/macd/article/view/1509}, DOI={10.4081/monaldi.2020.1509}, abstractNote={<p>Sarcoidosis is a chronic granulomatous disease of unknown etiology. The disease  most commonly involves the lungs and the mediastinal lymph nodes while extrapulmonary organs such as the skin, eye, liver or spleen may also be comprised. Many imaging modalities have been used for the clinical evaluation of sarcoidosis patients but all have been found to have certain drawbacks for a reliable identification assessment due to the equivocal diagnostic results.  This case series was designed to determine the clinical trenchancy of simultaneous<sup> 68</sup>Ga citrate PET/CT [Positron emission tomography with <sup>68</sup>Ga citrate (<sup>68</sup>Ga citrate PET/CT)] and <sup>18</sup>F-FDG PET/CT [Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography (<sup>18</sup>F-FDG PET/CT)] imaging in sarcoidosis patients. The main goal of the study was to evaluate sarcoidosis with respect to disease activity and organ involvement. A total of eight sarcoidosis patients with a comorbid disease suspicion were included in the study. Conventional clinical parameters used for  the diagnosis and the activity of sarcoidosis including CT [Computed tomography (CT)] were compared with the <sup>68</sup>Ga-citrate PET/CT findings. Concurrent <sup>18</sup>F-FDG PET/CT was performed to verify the granulomatous inflammation of sarcoidosis and to determine coexisting malignant or other inflammatory diseases. Our study results revealed that <sup>68</sup>Ga citrate PET/CT imaging appears to be highly useful for the diagnosis, activity assessment and extrapulmonary organ involvement in sarcoidosis. Another crucial finding was the detection of extrapulmonary organ disease that are exceptionally involved, almost inaccessible by biopsy and that could not be otherwise displayed by other conventional imaging modalities. The third hallmark was the identification of a clinically asymptomatic and occult malignancy accompanying sarcoidosis that would not be revealed in any way if synchronous <sup>18</sup>FDG PET/CT had not been performed. Simultaneous application of <sup>68</sup>Ga citrate and <sup>18</sup>FDG PET/CT may provide extremely useful data for the clinical evaluation of sarcoidosis patients in terms of the primary disease diagnosis, activity state, extrapulmonary organ involvement unachievable for biopsy and the clinically occult malignant disorders.</p>}, number={4}, journal={Monaldi Archives for Chest Disease}, author={Tetikkurt, Cuneyt and Yanardag, Halil and Sayman, Burcak Haluk and Bilir, Muammer and Tetikkurt, Seza and Bilgic, Seckin and Kubat, Bahar and Bilgin, Seyda}, year={2020}, month={Dec.} }